-
HutchMed and AstraZeneca’s Tagrisso-Orpathys Combo Shows Promise in NSCLC Study
•
Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) and AstraZeneca (AZ, NASDAQ: AZN) announced the preliminary results of the Phase II SAVANNAH study evaluating the combination of Tagrisso (osimertinib) and Orpathys (savolitinib) in patients with epidermal growth factor receptor – mutated (EGFRm) non-small cell lung cancer (NSCLC) with high levels…
-
NMPA Accepts Roche’s Crovalimab Filing for PNH Treatment with Priority Review
•
The National Medical Products Administration (NMPA) has officially accepted for review the market filing submitted by Swiss pharmaceutical giant Roche for its paroxysmal nocturnal hemoglobinuria (PNH) drug, crovalimab, granting it priority review status. About PNHPNH is a rare and fatal blood system disease with an incidence of approximately 1 to…
-
Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in a Phase I clinical study of its GT20029 for androgenetic alopecia and acne in China. The randomized, double-blind, placebo-controlled study assessed the safety and pharmacokinetics of GT20029 (gel / tincture) in healthy subjects via single…
-
NHSA Cracks Down on Price Gouging in Basic Medical Insurance Scheme
•
The National Healthcare Security Administration (NHSA) has announced the results of a special investigation, revealing that three companies have been found guilty of price gouging and defrauding funds from the Basic Medical Insurance (BMI) scheme. The companies involved are Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd, Guangzhou Baiyunshan General Factory, and…
-
FibroGen’s Roxadustat Sales in China Rise Despite Price Cut
•
US firm FibroGen Inc. (NASDAQ: FGEN), which operates subsidiaries in Beijing and Shanghai, released its Q2 2022 financial results, including updates on the China market performance of its anemia therapy roxadustat (trade name: Evrenzo). The drug, a global first-in-class oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, is distributed in China via…
-
Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study
•
China-based Inmagene Biopharmaceuticals and Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the first subject has been dosed in the US in a global Phase I clinical study for their drug candidate IMG-004. The double-blind, randomized, placebo-controlled, single and multiple dosage escalation study is designed to assess the…
-
Zai Lab’s Q2 2022 Financials Show Revenue Growth and R&D Cost Cut
•
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 2022 financial report, recording USD48.2 million in total revenues during the period, up 30.62% year-on-year (YOY). The company’s research and development (R&D) expenditure was USD66.1 million, down 53.52% YOY. Zai generated a USD137.9 million net loss, compared with…
-
BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study
•
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the global Phase III RATIONALE 301 study evaluating tislelizumab in first – line unresectable hepatocellular carcinoma (HCC) has met its primary endpoint. The study demonstrated that the programmed death – 1 (PD – 1) inhibitor tislelizumab was non – inferior to…
